|
🐜
|
The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes.
29 auth.
G. Bray,
K. Polonsky,
P. G. Watson,
R. Goldberg,
S. Haffner,
R. Hamman,
E. Horton,
S. F. Kahn,
A. Kitabchi,
B. Metzger,
D. Nathan,
J. Olefsky,
F. Pi‐Sunyer,
M. Prince,
R. Ratner,
...
M. Saad,
S. Jack,
C. Saudek,
D. Schade,
H. Shamoon,
R. Wing,
R. Arakaki,
W. C. Krowler,
Bain Rp,
S. Marcovina,
P. Rautaharju,
E. Mayer‐Davis,
D. O'leary,
E. Stamm
|
9 |
1999 |
9
🐜
|
|
🐬
|
Bed-rest-induced insulin resistance occurs primarily in muscle.
C. Stuart,
R. Shangraw,
M. Prince,
E. Peters,
R. Wolfe
|
8 |
1988 |
8
🐬
|
|
🐬
|
The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus
S. Rosenblatt,
B. Miskin,
N. Glazer,
M. Prince,
K. E. Robertson
|
7 |
2001 |
7
🐬
|
|
🐢
|
Effects of vitamin D on insulin and glucagon secretion in non-insulin-dependent diabetes mellitus.
E. Orwoll,
M. Riddle,
M. Prince
|
7 |
1994 |
7
🐢
|
|
🐜
|
Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes.
8 auth.
V. Grotz,
R. Henry,
J. McGill,
M. Prince,
M. Prince,
H. Shamoon,
...
J. Trout,
F. Pi‐Sunyer
|
7 |
2003 |
7
🐜
|
|
🐜
|
Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes.
8 auth.
V. Grotz,
R. Henry,
J. McGill,
M. Prince,
M. Prince,
H. Shamoon,
...
J. Trout,
F. Pi‐Sunyer
|
7 |
2003 |
7
🐜
|
|
🐜
|
A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 Diabetes
8 auth.
R. Bergenstal,
J. Rosenstock,
R. Arakaki,
M. Prince,
Y. Qu,
V. Sinha,
...
D. Howey,
S. Jacober
|
6 |
2012 |
6
🐜
|
|
🦁
|
Direct in vitro effect of a sulfonylurea to increase human fibroblast insulin receptors.
M. Prince,
J. Olefsky
|
6 |
1980 |
6
🦁
|
|
🐬
|
Insulin responsiveness of protein metabolism in vivo following bedrest in humans.
R. Shangraw,
C. Stuart,
M. Prince,
E. Peters,
R. Wolfe
|
6 |
1988 |
6
🐬
|
|
🐢
|
Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin‐naïve or previously treated with insulin glargine: a randomized, double‐blind controlled trial (the ELEMENT 2 study)
8 auth.
J. Rosenstock,
P. Hollander,
A. Bhargava,
L. Ilag,
Robyn K. Pollom,
J. Zielonka,
...
W. Huster,
M. Prince
|
6 |
2015 |
6
🐢
|
|
🐜
|
Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes
9 auth.
J. Rosenstock,
R. Bergenstal,
T. Blevins,
L. Morrow,
M. Prince,
Y. Qu,
...
V. Sinha,
D. Howey,
S. Jacober
|
6 |
2013 |
6
🐜
|
